Astrazeneca (AZN) Accounts Payables (2009 - 2026)

Astrazeneca has reported Accounts Payables for 18 years, with the latest figure at -$22.9 billion in Q2 2026.

• On a quarterly basis, Accounts Payables rose 4.56% year-over-year to -$22.9 billion in Q2 2026; TTM through Jun 2026 was -$22.9 billion, a 4.56% increase from a year earlier, with the FY2025 full-year figure at -$25.3 billion, down 12.53% from the prior year.
• Accounts Payables was -$22.9 billion for Q2 2026 at Astrazeneca, down from -$22.5 billion in the prior quarter.
• The five-year high for Accounts Payables was -$17.7 billion in Q3 2022, with the low at -$25.3 billion in Q4 2025.
• Average Accounts Payables over 5 years is -$21.2 billion, with a median of -$21.1 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables advanced 5.19% in 2022, then decreased 17.51% in 2023.
• Over 5 years, Accounts Payables stood at -$19.0 billion in 2022, then dropped by 17.51% to -$22.4 billion in 2023, then declined by 0.41% to -$22.5 billion in 2024, then fell by 12.53% to -$25.3 billion in 2025, then advanced by 9.44% to -$22.9 billion in 2026.
• The last three Accounts Payables figures came in at -$22.9 billion (Q2 2026), -$22.5 billion (Q1 2026), and -$25.3 billion (Q4 2025), per Business Quant data.